SCHEMBL4423346

SCHEMBL4423346

Cc1nc(-c2ccc(F)c(F)c2)ccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.66
SMN1; SMN2 Q16637 4/20 0.65
ALDH1A1 P00352 2/20 0.62
RAB9A P51151 4/20 0.58
KMO O15229 5/20 0.55
NPC1 O15118 3/20 0.50
CASP3 P42574 2/20 0.50
SENP8 Q96LD8 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
SENP6 Q9GZR1 2/20 0.50
KDM4E B2RXH2 2/20 0.48
MAPT P10636 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HPGD P15428 1/20 0.47
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
GABRA1 P14867 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2765423 0.83 SMN1; SMN2 (0.76) RXFP1SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL4433477 0.82 RAB9A (0.65) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO
SCHEMBL4427419 0.81 ALDH1A1 (0.69) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO
SCHEMBL4412318 0.80 SMN1; SMN2 (0.76) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO
SCHEMBL4424436 0.79 SMN1; SMN2 (0.65) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO
SCHEMBL4429929 0.77 ALDH1A1 (1.00) RXFP1SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL1550372 0.76 SMN1; SMN2 (0.69) RXFP1SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL3758452 0.75 KMO (0.58) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO
SCHEMBL19645881 0.75 SMN1; SMN2 (0.69) RXFP1SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL4434614 0.75 KMO (0.56) RXFP1SMN1; SMN2ALDH1A1RAB9AKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 RXFP1 181/4885SMN1; SMN2 3167/4885ALDH1A1 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.